1001 / 1578
C
onventional fractionation:
•
TD
50
in metastases patients < 46 Gy
•
TD
50
in primary liver cancer < 40 Gy
•
Dawson et al. IJROBP 53: 810; 2002
•
TD
50
in non-HBV carriers: 50 Gy
•
TD
50
in HBV carriers: 46 Gy
•
Cheng et al. IJROBP 60:1502; 2004
Dawson et al. 2002
The risk of RILD calculated using LymanKutcher-
Burman (LKB) NTCP model parameters for RILD
obtained from patients treated at 1.5 Gy per fraction
(n/0.97, m/0.12, TD50 (metastases)/45.8 Gy, TD50
(primary cancer)/39.8 Gy)
NTCP based dose prescription
Risk adapted